The FDA restarted the flow of pharma complete response letters (CRLs), posting 14 new rejection letters online. The agency’s return to publishing these decisions follows an earlier pause tied to concerns raised by a pharma-backed effort described in reporting. Separate threads in the batch point to manufacturing- or compliance-related issues as a recurring cause of CRLs, with companies often required to address facility inspection findings or other procedural deficiencies before reconsideration. For biotech and specialty pharma, the operational shift is notable because CRL timing affects trial timelines, resubmission strategies, and financing narratives—especially for companies planning launches or seeking to unlock market access under tight development calendars.